Curevac doses first patient in phase 1 study of cancer vaccine candidate for surgically resected glioblastoma

Cancer vaccine candidate cvgbm utilizes single mrna, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastoma study designed to evaluate safety and immunogenicity in patients with glioblastoma after surgical resection and radiotherapy first study to apply curevac's second-generation mrna backbone in oncology tÜbingen, germany and boston, ma / accesswire / june 20, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that it has dosed the first patient with its investigational cancer vaccine cvgbm in a phase 1 study.
CVAC Ratings Summary
CVAC Quant Ranking